MGB BP 3

Drug Profile

MGB BP 3

Alternative Names: MGB-BP-3

Latest Information Update: 29 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MGB Biopharma
  • Class Antibacterials; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Clostridium infections
  • Preclinical Gram-positive infections; Skin and soft tissue infections

Most Recent Events

  • 12 Sep 2016 MGB BP 3 is available for licensing as of 12 Sep 2016. http://www.mgb-biopharma.com/
  • 12 Sep 2016 MGB BP 3 receives Qualified Infectious Disease Product status for Clostridium infections (Clostridium difficile-associated diarrhoea) in USA
  • 09 May 2016 MGB Biopharma plans a phase II trial for Clostridium infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top